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Immunogenicity and clinical efficacy
of influenza vaccination in pregnancy
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Pregnant women are at high risk from influenza due to disproportionate morbidity, mortal-
ity, and adverse pregnancy outcomes following infection. As such, they are classified as
a high-priority group for vaccination. However, changes in the maternal immune system
required to accommodate the allogeneic fetus may alter the immunogenicity of influenza
vaccines. A large number of studies have evaluated the safety of the influenza vaccine.
Here, we will review available studies on the immunogenicity and efficacy of the influenza
vaccine during pregnancy, focusing on both humoral and cellular immunity.
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Introduction
Pregnant women are at increased risk of severe disease secondary to influenza infection, particularly
during influenza pandemics. In the 1918 influenza pandemic, maternal mortality was 27% (1), and
in one report from the1957 pandemic, half of the fatal cases in reproductive-aged women were
among those that were pregnant (2). Rates of hospitalization were higher among pregnant than non-
pregnant reproductive-aged women during the pandemics of 1918, 1957, and 2009 (1–3). Though
the increased rate of hospitalization in pregnant women is substantially less pronounced during non-
pandemic years, pregnantwomen are still at increased risk from seasonal influenza (4, 5), particularly
during the third trimester (6).
As early as 1962, the U.S. Public Health Service identified pregnant women as a priority group
for influenza vaccination. However, questions then and now have been raised about how preg-
nancy alters the quality of the immune response to influenza vaccination. It is generally believed
that alterations in immune function contribute to increased influenza severity during pregnancy.
Logically, it has also been hypothesized that vaccination during pregnancy may result in a less
favorable immunologic response. Immunomodulation during pregnancy has been the subject of
several recent reviews (7–10). Here, we will focus, instead, on reviewing the history and evidence on
the immunogenicity of the influenza vaccine during pregnancy and its clinical efficacy.
Assessment of Immunogenicity
To place the existing studies in context, a brief review of the methods used to assess the immune
response to vaccination, or immunogenicity, is warranted. The “gold standard” method is the
hemagglutinin inhibition (HI) titer, which measures the concentration of antibody required to
prevent influenza from agglutinating red blood cells. Thus, the HI titer is a measure of the total
amount of antibodies to the hemagglutinin (HA) protein. The WHO defines a “protective” titer
as 1:40, based on a 50% reduction in disease, and thus the term seroprotection refers to those
individuals with a titer of 1:40 or better (11). Seroconversion is defined as an increase in HI titer
following vaccination of fourfold or greater. Virus microneutralization (VMN) assays measure the
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ability of antibodies in serum to prevent a specific strain of
influenza from infecting a cell line, typicallyMadin–Darby canine
kidney epithelial cells. This assay therefore measures the func-
tional capability of antibodies at a specific dilution, rather than
just the total quantity. In settings of impaired host immunity,
such as HIV infection, the VMN titer is more sensitive than
the HI titer (12); VMN is also better for detecting antibodies to
avian influenza viruses (13). Multiple studies have demonstrated
good correlation between HI titers and VMN titers in pregnant
women following monovalent H1N1 vaccination (14, 15), and
now seasonal influenza vaccination (16).
Immunogenicity of Influenza Vaccine in
Pregnant Women
In 1962, when a resurgence of the 1957 A2 pandemic influenza
strain was anticipated, the U.S. Public Health Service identified
pregnant women as a priority group for vaccination based on
their historically poor outcomes. However, due to concerns that
the same immune alterations that led to increased morbidity
could compromise the immune response to the vaccine during
pregnancy, Hulka compared the immunogenicity of the vaccine
between pregnant and non-pregnant women (17). This placebo-
controlled clinical trial compared immune responses after two
doses of inactive polyvalent influenza vaccine containing 200U of
A2 antigen and placebo. Overall, in those receiving the vaccine,
pooled and individual complement fixation titers were similar
between pregnant and non-pregnant women. Further, pooled
titers in the non-vaccinated groups were also similar, though
they rose at a later time point following circulation of influenza
virus in the community. Interestingly, in this study, there was
only a marginal, and not-statistically significant, decrease in
the rates of influenza-like illness in those receiving the vac-
cine, whether pregnant or not. While these results indicate that
pregnancy did not appear to compromise the immunogenicity
of the vaccine, Hulka also did not observe increased disease
severity in pregnant women during the 1962 season (17). Con-
sistent with these results, there was no evidence of increased
morbidity or mortality in pregnant women from 1958 to 1962
(18). There was also no evidence of increased morbidity and
mortality during the 1968 pandemic, which had variable global
penetration (19). Thus, the risks posed to pregnant women by
influenza may differ according to the circulating strain in a
given year. This is an important consideration in evaluating
immunogenicity, because it remains possible that differences in
the immune response to vaccination could also differ based on
vaccine strain.
Without clear evidence for increased morbidity and mortality
among pregnant women in 1960s, influenza vaccination of preg-
nant women during seasonal epidemics was deemphasized as a
public health approach until 1976–1977, when a novel influenza
strain with pandemic potential emerged at Fort Dix, NJ, USA.
The influenza outbreak was ultimately confined to the military
base, but in preparation for its spread, approximately 25% of
the U.S. population was vaccinated with a novel monovalent
A/New Jersey/8/76 (Hsw1N1) vaccine. Vaccine responses to this
novel monovalent vaccination were compared between pregnant
women and non-pregnant women by HI titers and by using 2-
mercaptoethanol treatment to assess the amount of IgM antibody
(20). As with the prior study by Hulka, no significant differences
between pregnant and non-pregnant women were observed in the
geometricmean titers (GMT) following vaccination, norwas there
a significant difference in the mercaptoethanol IgM reduction
indicative of antigen-specific IgM. Together, these two studies
suggested that pregnantwomenhad vaccine responses on parwith
those of non-pregnant women.
In 1990s and early 2000s, increased attention was given to vac-
cination of pregnant women. In 1997, the American Committee
on Immunization Practice recommended seasonal influenza vac-
cination for pregnant women in the second and third trimesters,
and in 2004, this recommendation was modified to include all
pregnant women. In 2008, a large randomized-controlled trial
of vaccination in pregnant women in Bangladesh demonstrated
that influenza vaccination was clinically efficacious in preventing
influenza in pregnantwomen and their infants (21). The immuno-
genicity data from this trial were subsequently released in 2010
(22). In this study, there was no non-pregnant control group, but
the pregnant women had significant increases in their GMTs to
the H1N1, H3N2, and influenza B strains following vaccination,
and seroconversion rates of 83.6% forH1N1, 69.2% forH3N2, and
39.7% for B influenza strains (22), which are similar to those seen
among healthy adults receiving seasonal influenza vaccination.
Early reports that pregnant women were experiencing dis-
proportionate morbidity and mortality during the 2009 H1N1
pandemic prompted renewed interest in the immunogenicity of
the inactivated influenza vaccine (IIV) in pregnant women (3).
Multiple studies evaluated immune responses to the monova-
lent pH1N1 vaccination during pregnancy. Ohfuji et al. enrolled
150 pregnant women receiving the thimerosal-free monovalent
pH1N1 (15µg) vaccination during pregnancy (23). Immune
responses were tested by HI titers 3weeks after the first dose and
4weeks after the second dose, controlling for body mass index,
age, and the receipt of the 2009 seasonal influenza vaccination.
Robust responses were noted to the initial vaccination, with an
average HI antibody increase of more than 10-fold and a sero-
conversion rate of 91%. The second vaccination conferred little
additional benefit. Importantly, it was noted that receipt of sea-
sonal influenza vaccination<19 days prior to pH1N1 vaccination
significantly reduced the fold increase in titer (p= 0.021).
A similar study by Tsatsaris et al. enrolled 110 women equally
divided between the second and third trimester of pregnancy who
received a single dose of monovalent pH1N1 containing 15µg of
HA (15). Subjects were evaluated with HI and VMN assays pre-
vaccine and at 21 and 42 days after vaccination. Infant cord-blood
titers were also assessed. Pregnant women responded robustly in
this study as well: 21 days post-vaccination 98% of women had HI
titers of>1:40 (seroprotection) and 93%had seroconverted. It was
again noted that women with prior seasonal influenza vaccina-
tion had lower fold increases in GMT. In this study, a lower HI
GMT was observed in women with twin pregnancy (p= 0.006),
although it is unclear whether this is secondary to decreased
production or increased placental transfer of antibody. Maternal
and cord-blood titers were highly correlated (r= 0.86). Lastly,
VMN titers correlated significantly with HI titers (r= 0.96).
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Jackson et al. also evaluated responses to the monovalent
H1N1 vaccine in pregnant women, investigating whether preg-
nant women responded differently to a vaccination containing
49µg HA as compared to 25µg HA (14). HI and VMN assays
were again used to evaluate vaccine responses. Following the first
vaccination, 93% of women had titers of >1:40 (seroprotection).
The second vaccination did not significantly increase antibody
titers, and there was no benefit to using the higher antigen content
vaccine. As with Tsatsaris et al., VMN and HI responses were
significantly correlated (r= 0.81) following vaccination. However,
unlike the other two studies, prior receipt of seasonal influenza
vaccination was not associated with decreased responses to the
monovalent vaccine. Zuccotti et al. published a study of adju-
vanted pH1N1 in pregnant women that resulted in titers con-
sistent with seroprotection in 100% of pregnant women, but did
not include a pre-vaccine timepoint (24). Overall, though none
of these studies included non-pregnant women, the percentage of
pregnant women seroconverting and achieving protective titers
was similar to studies of the pH1N1 monovalent vaccine per-
formed on non-pregnant men and women (25, 26). However,
comparisons with cohorts including men and women are limited
by the fact that non-pregnant women respondmore robustly than
men to influenza vaccination (27, 28). Despite this caveat, as a
whole, these studies did not reveal any immunologic deficits, as
measured byHI andVMN, to themonovalent pH1N1 vaccination
in pregnant women.
Several studies have evaluated vaccine responses to modern
seasonal IIV in pregnant women, although only two have included
non-pregnant women as a control group. Sperling et al. performed
a large multiyear study of 239 pregnant or postpartum women
vaccinated with the seasonal influenza vaccine between October
2006 and January 2010, in addition to monovalent H1N1 vaccina-
tion in 2009–2010 (29). Overall, the timing of vaccination during
pregnancy did not significantly alter HI GMT responses, although
there was a trend toward lower responses in the first trimester and
6weeks postpartum. Seroprotection for H3N2 ranged from 65 to
95% and for H1N1 from 75 to 98%, with higher baseline titers
and receipt of vaccination in the prior year associated with lower
rates of seroconversion. They found that antibody responses were
dominated by IgG1 regardless of trimester.
Along similar lines, Madhi et al. evaluated clinical efficacy and
immunogenicity of seasonal trivalent IIV in 2011 and 2012 in
South African pregnant women between 20 and 36weeks gesta-
tional age compared to placebo. HIV-uninfected pregnant women
responded robustly to IIV with high rates of seroprotection to all
vaccine strains (30), though responses were not compared to those
of non-pregnant women. In the HIV-infected cohort, the percent-
age of women with seroprotection was lower; however, HI titers
in this group may have underestimated vaccine efficacy, which
was 70.6% to confirmed influenza infection. VMNassays were not
performed but given prior data on HI titers in HIV infection (12),
it is not surprising that HI titers may have underestimated efficacy
in this group. Importantly, there was no increase in HIV viral load
following maternal vaccination.
Schlaudecker et al. compared HI responses to the 2011–2012
seasonal IIV3 between pregnant women (n= 29) and non-
pregnant women (n= 22) of similar ages (31). They found that
while pregnant and control women achieved seroconversion
and seroprotection at similar rates, pregnant women had lower
post-vaccination GMTs to A/California (H1N1) (p= 0.027) and
A/Perth (H3N2) (p= 0.037). This cohort was unique with respect
to prior vaccination history in that 97% of pregnant women and
96% of non-pregnant women had received the influenza vac-
cination in the previous year. This may suggest that pregnant
women are less able to mount serologic responses to previously
encountered influenza antigens. However, this would seem to
contradict epidemiological data suggesting only subtle differences
in disease severity following seasonal influenza infection during
pregnancy.
Kay et al. evaluated responses to the 2012–2013 seasonal IIV3
in pregnant women (n= 20) and non-pregnant women (n= 18)
of similar ages. The cohorts were matched by age, but the non-
pregnant womenweremore likely to have received prior influenza
vaccinations and had higher baseline HI titers. In contrast to the
findings of Schlaudecker et al., pregnant women in this study had
equivalent post-vaccination HI titers to those of non-pregnant
women for pH1N1 and B/Wisconsin and higher HI fold-change,
even after controlling for baseline titers, for the pH1N1 and
B/Wisconsin strains (p= 0.016 and p= 0.014, respectively). This
study included VMN titers, which significantly correlated with HI
titers across all strains tested. Unlike the HI titers, there were no
significant differences in VMN response between pregnant and
control women after controlling for baseline VMN titer. Further,
pregnant women had higher total IgG levels before immunization
(p= 0.042) but not following vaccination. Thus, no deficit in the
quantity or quality of the antibody response to seasonal IIV was
noted in pregnant women in this study.
Kay et al. also assessed the induction of plasmablasts, antibody-
secreting, activated B cells, in pregnant and non-pregnant women,
relying on data collected in the 2010–2011, 2011–2012, and
2012–2013 seasons. Pregnant women had a significantly greater
induction of plasmablasts following vaccination than did non-
pregnant controls (p= 0.03), though this difference was no longer
significant when comparing a small number of pregnant and
control women from the 2012 to 2013 influenza season alone.
In this study, pregnancy remained predictive of increased plas-
mablast induction after controlling for baseline average HI titer,
suggesting an enhanced induction of antibody-secreting B cells
during pregnancy.
Overall, these data suggest that the immunogenicity of IIV,
based on the induction of antibodies, is similar in pregnant and
non-pregnant women. However, differences in vaccine responses
to different influenza strains may complicate our ability to assess
subtle changes in responses among pregnant women. Further,
responses vary based on prior vaccination or exposure, and preg-
nant women may mount less robust antibody responses to a sec-
ondary challenge. The comprehensive data from pH1N1 mono-
valent vaccination suggests that pregnant women mount robust
antibody responses to a novel influenza vaccine.
Induction of Cellular Responses
Most studies of influenza vaccine immunogenicity have focused
on the induction of antibodies as the correlate of protection.
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However, several recent studies have evaluated cellular immune
responses within peripheral blood mononuclear cells (PBMCs).
Forbes et al. compared the induction of cytokines by ELISA,
cytometric bead array, and mRNA levels between pregnant and
non-pregnant women whose PBMCs were cultured for 48 h with
pH1N1 (32). Production of interferon protein and mRNA was
reduced in pregnant women who were unvaccinated (N = 12)
compared with healthy controls, suggesting a deficit in interferon
induction during pregnancy. However, interferon production
normalized in pregnant women that had undergone pH1N1 vac-
cination during the prior 12months, suggesting that vaccination
could rescue this defect. Supporting the idea that pregnant women
had decreased interferon production, expression of the mRNA
encoding protein kinase R, an early interferon stimulating gene,
was reduced in pregnant women (32). There were no differences
between pregnant and non-pregnant women in the expression of
genes encoding the toll-like receptor-3 (TLR3), TLR7, and TLR 9,
nor was there a difference in the ability of PBMCs from pregnant
or non-pregnant women to support viral replication (32). Subse-
quently, Vanders et al. found that the percentage of plasmacytoid
DCs was reduced in pregnant women and that PDL-1, CD86,
and HLA-DR are upregulated on plasmacytoid DCs in pregnancy
(33). Blocking antibodies to PD1/PDL1 in pH1N1 PBMC cultures
from pregnant women resulted in increased production of IFN-
α and IFN-γ, suggesting that deficits in interferon production
during pregnancy could be rescued by blocking these inhibitory
pathways.
Recently, Kay et al. evaluated NK and T cell responses of preg-
nant women (n= 21) and controls (n= 29) to pH1N1 and H3N2
infection of PBMCs ex vivo for 7 h (34). Consistent with earlier
data, pregnant women had lower IFN-γ production, as measured
by intracellular cytokine staining, than did non-pregnant women
following stimulation of PBMCs with phorbol 12-myristate 13-
acetate and ionomycin. However, in response to influenza infec-
tion, the NK and T cells from pregnant women had significantly
increased MIP-1β production and enhanced polyfunctional NK
and T cell responses compared to non-pregnant women. In this
study, vaccination did not significantly affect T orNK cell cytokine
and chemokine responses in pregnant women or controls. The
assay performed in this study was of shorter duration and used
a higher multiplicity of infection than did the assay described by
Forbes et al. and Vanders et al. In addition, it is likely that both the
pregnant and control women in this study could have been either
previously infected by or vaccinated against pH1N1.
In addition to intracellular cytokines, researchers have also
evaluated the impact of pregnancy on serum cytokines before and
after IIV. Christian et al. compared serum levels of IL-6, TNF-α,
IL-8, IL-1β, and migration inhibitory factor (MIF) in 28 preg-
nant women (average weeks gestational age= 28.4) and 28 non-
pregnant healthy women immediately prior to IIV and 1, 2, and
3 days following vaccination (35). Baseline levels of IL-8 and MIF
were significantly higher in non-pregnant women. There was no
difference in pregnant vs. non-pregnant women in IL-6, TNF-α,
or IL-1β responses to vaccination. Pregnant women experienced
an increase in MIF levels and no change in IL-8 levels, while non-
pregnant women had decreases in both post-vaccination. This
group also evaluated HI responses pre- and post-vaccination and
found no difference in seroconversion or seroprotection between
groups.
Overall, additional study of cellular responses is needed to
understand how pregnancy modifies these responses, as a clear
picture has not yet emerged. Some data would suggest a deficiency
in interferon production, yet other inflammatory pathways may
be elevated in response to influenza infection and vaccination
during pregnancy. These differences could well be a result of the
specific cell types being assessed, kinetic variations in the immune
response, or disparities in prior exposure to the influenza strains
studied.
Vertical Antibody Transfer
Vertical transfer of maternal antibodies to the fetus is of equal
importance when evaluating influenza vaccine immunogenic-
ity in pregnant women. To this end, Sumaya et al. investigated
the immunogenicity of the 1976 monovalent A/New Jersey/8/76
(Hsw1N1) influenza vaccine in 26 maternal serum and cord-
blood pairs at the time of delivery. A titer of 20 by HI was
considered protective against influenza in this study. The GMT
of newborn cord bloods was 23.6 and 54% of specimens had
protective titers. The GMT of maternal serum was 35.8 and
73% had protective titers. Newborn titers were not significantly
affected by the trimester of maternal vaccination (second vs.
third). However, the antibodies waned in the infants by 3months
following delivery, when only 12% of infants but 92% of mothers
had protective titers. The magnitude of the maternal antibody
response correlated strongly with the infant’s antibody titer at
3months of age (r= 0.77, p< 0.01). Thus, the authors concluded
that passive transfer of antibody did occur, though it appeared
to be relatively short-lived. A second study by Englund et al.
evaluated placental transfer ofmaternal antibody to tetanus toxoid
and seasonal IIV (36). The 13women vaccinatedwith seasonal IIV
had robust antibody responses to all three strains as measured by
ELISA. The infants had comparable levels of antibody at birthwith
infant/mother antibody ratios of between 94 and 99% for all three
strains (36).
In 2009, Tsatsaris et al. evaluated cord-blood titers in addition
to maternal immunogenicity and found that maternal and cord-
blood titers correlated (r= 0.86). Infant titers of 1:40 or greater
were observed in 95% [confidence interval (CI) 89–99%] of the
88 cord-blood samples tested, and cord-blood titers were sig-
nificantly higher than maternal blood titers. Neither gestational
age at vaccination nor delivery significantly affected the neonatal
seroprotection rates. Similar results were obtained by Jackson et al.
(14). Cord-blood HI GMTs were higher than maternal titers at
both vaccine doses and significantly so for the 49µg dose group
(p= 0.002). In this study, there was a trend toward lower cord-
blood titers with longer intervals between the time of vaccina-
tion and delivery. In both of these studies, the cord-blood titers
were higher than maternal titers, suggesting active transfer of
antibodies across the placenta.
Further confirmation of vertical antibody transfer has come
from the randomized-controlled trials of influenza vaccine effi-
cacy in pregnant women. In the study performed in Bangladesh,
there was no difference in maternal and infant cord-blood HI
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TABLE 1 | Studies evaluating IIV and monovalent pH1N1 vaccine responses during pregnancy.
Reference Vaccine, years Study participants Immune assays
and outcomes
Vaccine response Summary
IMMUNOGENICITY OF MODERN SEASONAL INACTIVATED INFLUENZA VACCINE (IIV) IN PREGNANT WOMEN
Steinhoff
et al. (22),
Zaman et al.
(21)
Seasonal IIV
2004
340 pregnant
Bangladeshi women in
the third trimester
HI titers pre- and
post-vaccination. Influenza
disease endpoints
Seroprotection for H1N1 88%,
H3N2 98%, and B 45%. Ratio
of maternal to infant titers at
delivery ranged from 0.7 to 1.7
High rates of seroconversion and
seroprotection following IIV in
pregnant women. Reduction in
febrile respiratory illness in
mothers. Reduction in
laboratory-confirmed influenza in
infants
Sperling
et al. (29)
Seasonal IIV
2006–2010 and
H1N1
vaccination
2009–2010
239 pregnant women
(73 first, 183 second,
142 third Trimester, 73
immediately postpartum,
36 6weeks postpartum
HI Titers pre- and
post-vaccination to
influenza A strains
Seroprotection for H3N2 varied
from 65 to 95% and between
75 and 98% for H1N1 strains.
No significant difference in
seroprotection or seroconversion
by trimester or postpartum. No
differences in IgG subtype
production in pregnancy vs.
postpartum
IgG subtyping pre- and
post-vaccination
Christian
et al. (35)
Seasonal IIV,
2011–2012
28 pregnant women
(average gestational age
28.4weeks) and 28
non-pregnant women
Serum cytokines (prior to,
1, 2, and 3days
post-vaccination) and HI
titers pre- and 1 month
post-vaccination
Seroprotection rates in
pregnant vs. control for H1N1
(89 vs. 85%), H3N2 (81 vs.
93%), and B (83 vs. 100%)
were not-statistically different.
There were also no significant
differences in seroconversion
High rates of seroprotection and
seroconversion were observed in
both groups. There was not a
significant effect observed
secondary to vaccination in the
prior year. See text for a review
of the cytokine responses
Schlaudecker
et al. (31)
Seasonal IIV,
2011–2012
29 pregnant women, all
trimesters, 22
non-pregnant women
HI titers pre- and post-
vaccination
Seroprotection H1N1
93–100%, H3N2 100%, B
58.6–68.2%. Post-vaccination
H1N1 GMT 152.53 pregnant
vs. 300.46 control, H3N2 GMT
142.0 pregnant vs. 241.0
control
No difference between pregnant
and control groups in
seroprotection, seroconversion,
or fold increase. Significantly
increased post-vaccination titers
to H1N1 and H3N2 in control
women
Greater than 96% of
participants received
vaccine in the prior year
Madhi et al.
(30)
Seasonal IIV,
2011–2012,
2012–2013
2116 pregnant women
were enrolled, 1062
received IIV, and 1054
received placebo. All
trimesters included. An
HIV positive subset was
included
HI titers pre-vaccination
and 28–35days
post-vaccination. Multiple
influenza disease
endpoints evaluated
Seroprotection to H1N1
93.3%, H3N2 78.0%, and B
96%. Overall vaccine efficacy of
preventing confirmed influenza
54.4%. Seroprotection in
HIV-infected was 48.6% H3N2
and 68.6% H1N1, but vaccine
efficacy was 70.6% in this
subset
High levels of seroprotection for
HIV-uninfected women
post-vaccination. Decreased
seroprotection in HIV-infected
women but increased vaccine
efficacy. Protection from
laboratory-confirmed influenza in
pregnant women and their
infants
Kay et al.
(16)
Seasonal IIV,
2012–2013
20 pregnant women,
second and third
trimesters, 18
non-pregnant women.
Significantly fewer
pregnant women had
received the vaccination
in the prior year
HI titers, VMN titers, and
plasmablast identification
pre- and post-vaccination
Seroprotection H1N1 100%,
H3N2 94.4–100%, B
77.8–90.0%. HI and VMN titers
were strongly correlated for
each strain. Plasmablasts
1.32% pregnant vs. 0.46%
control 7 days post-vaccination
(p= 0.03)
No difference in post-vaccination
titers in pregnant vs. control
women. Increased fold-changes
and decreased pre-vaccine titers
in pregnant women. Possibly
increased plasmablast induction
in pregnant women
Reference Vaccine, dose Study participants Immune assays Vaccine response Summary
IMMUNOGENICITY OF MONOVALENT PH1N1 VACCINE IN PREGNANT WOMEN
Zuccotti
et al. (24)
MF59
adjuvented
pH1N1
monovalent
vaccine (7.5µg)
75 pregnant women
(third trimester). Infants
were also enrolled
through 5months
HI titers were collected at
delivery, 2months and
5months post-delivery.
No pre-vaccination titer
Seroprotection in 100% of
pregnant women at delivery, 2
and 5months. Seroprotection
in 95.6% of infants at delivery
and 2months and 81.2% at
5months. Infant/maternal
antibody ratio of 0.55 at
delivery
High rates of seroprotection in
pregnant women and their
infants following adjuvanted
pH1N1 vaccination. Persistent
protective antibody levels
through 5months in infants and
their mothers
(Continued)
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TABLE 1 | Continued
Reference Vaccine, dose Study participants Immune assays Vaccine response Summary
Ohfuji et al.
(23)
Two doses of
monovalent
pH1N1
vaccination
(15µg)
150 pregnant women, all
trimesters
HI titers before the first
vaccine, 3weeks after the
first vaccine and 4weeks
after the second dose
Seroprotection was observed
in 91% after the first dose. No
significant change was noted
after the second dose
High rates of seroprotection were
seen after one dose of the
vaccine. Receipt of seasonal
influenza vaccination <19days
prior to receipt of the monovalent
pandemic vaccination was
associated with decreased HI
responses
Tsatsaris
et al. (15)
Single dose of
monovalent
pH1N1 vaccine
(15µg)
110 women equally
divided between the
second and third
trimesters. Infant cord
bloods collected
HI and VMN titers pre-
and post-vaccination
Seroprotection was observed
in 98% post-vaccination and
93% of women seroconverted.
HI and VMN titers were highly
correlated (r= 0.96). Maternal
and infant cord-blood titers
were also correlated (r= 0.86)
High rates of seroprotection after
a single dose. Women with twins
had significantly lower
post-vaccination titers. Prior
seasonal influenza vaccination
was associated with lower fold
increase. Significantly higher
titers in cord blood suggesting
active transport of antibody
generated by IIV
Jackson
et al. (14)
Two doses of
monovalent
pH1N1 vaccine
at different
doses (25,
49µg)
120 women in the
second or third
trimester, 60 received
the 25µg and 60
received the 49µg
vaccine. Infant cord
bloods collected
HI and VMN pre and
post-vaccinations
93% of women met criteria for
seroprotection after a single
dose. No significant benefit to
two doses or the vaccine with
increased antigen content. HI
and VMN correlation (r=0.81).
GMR of cord-blood
titer/maternal titer was 1.81 in
the 25µg group and 2.96 in the
49µg group
High rates of seroprotection after
a single dose. No association
with vaccine response and prior
receipt of seasonal influenza.
Significantly higher titers in cord
blood suggesting active transport
of antibody generated by IIV
HI, hemagglutinin inhibition assay; VMN, viral microneutralization assay; GMT, geometric mean titer; GMR, geometric mean ratio; Seroprotection, HI titer1:40; Seroconversion, fourfold
or greater change in HI titer post-vaccination; IIV, inactivated influenza vaccine.
titers at the time of delivery (22). The infants whose mothers
were vaccinated continued to have elevated titers when compared
to infants of mothers vaccinated with pneumococcus vaccine
through 20–26weeks of life. The South African study by Madhi
et al. also evaluated cord-blood titers compared to maternal titers
1month after vaccination (30). The ratio of cord blood tomaternal
titers was 0.7 (0.6–0.8) for pH1N1 and for H3N2 and 0.8 (0.7–0.9)
for B/Victoria. Zuccotti et al. also evaluated cord-blood titers
followingmaternal vaccinationwith anMF-59 adjuvanted pH1N1
monovalent vaccine and found GMTHI titers of 141.8 at birth vs.
257.9 in the mothers, 106.5 at 2months and 38.3 at 6months in
the infants.
In summary, IIV during pregnancy results in efficient transpla-
cental transfer of the generated antibodies. While, most studies
have demonstrated equivalent titers in mothers at delivery and
cord-blood samples, some have shown elevated titers in cord
blood consistent with active antibody transport (37). While some
studies have hinted at lower cord-blood titers among pregnant
women vaccinated in the first trimester, it is unclear if this is
clinically significant. It has been demonstrated that a 2-week
window prior to delivery from the time of influenza vaccination
is necessary for placental antibody transfer (38). The maternal
antibodies are still present at 3months post-delivery, and wane
slowly thereafter. While maternal antibodies may suppress infant
responses to influenza vaccination at 1–2months of life (39), there
is no evidence to date suggesting a decreased response to influenza
vaccination at 6months of life.
Clinical Efficacy: Maternal
There is clinical data to evaluate the efficacy of influenza vaccina-
tion in reducing the incidence of influenza during pregnancy. Two
randomized-controlled trials have evaluated both maternal and
infant outcomes. In the study by Zaman et al., women vaccinated
with IIV during pregnancy had a 35.8% (CI 3.7–57.2) reduction
in febrile respiratory illness when compared to pregnant women
vaccinated with pneumococcus during pregnancy. In the study
by Madhi et al., of 2116 HIV-negative South African pregnant
women undergoing seasonal IIV vs. placebo, there was a 50.4%
(CI 14.5–71.2) reduction in laboratory-confirmed influenza.
This effect was also observed in HIV-infected pregnant women
(p= 0.03). However, in this trial, there was not a significant differ-
ence in the more non-specific diagnosis of influenza-like-illness.
The question of clinical efficacy has also been approached
through the use of large health databases. The efficacy of the
monovalent pH1N1 vaccine in pregnant women was evalu-
ated through an analysis of Norwegian health registries (40).
Approximately 54% of over 113,000 eligible pregnant women
received the monovalent pH1N1 vaccination. The risk of
receiving a clinical diagnosis of influenza was significantly
reduced in this group (adjusted hazard ratio, 0.30; 95% CI
0.25–0.34), suggesting that the monovalent pH1N1 vaccina-
tion was efficacious in pregnant women. The efficacy of sea-
sonal influenza vaccination has also been evaluated through
analysis of data from a large health plan in the U.S. (41).
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This was a case–control study over two influenza seasons using
a test negative design that estimated a vaccine efficacy of 44%
(CI, 5–67%). This was well within the range of efficacy estimates
for healthy adults in the same influenza seasons. Thus, both
randomized-controlled trials and database analyses suggest that
vaccination is efficacious in reducing maternal influenza.
Clinical Efficacy: Infants
There is even more substantial evidence suggesting that mater-
nal influenza vaccination reduces laboratory-confirmed influenza
and influenza related hospitalization in infants of vaccinated
mothers. This is critically important because infants <1 year of
age, and particularly those <6months of age, are at very high risk
for hospitalization from influenza infection (42). Further, infants
<6months are not vaccinated themselves because IIV does not
produce an adequate immune response in this age group, possibly
a result of the preexistingmaternal antibody (39). Fortunately, two
randomized-controlled trials have revealed a significant reduction
in clinical and laboratory-confirmed influenza in the infants of
vaccinated mothers (21, 30). The study by Zaman et al. of 340
mothers and their infants found that maternal vaccination with
IIV was associated with a vaccine efficacy of 63% (95%CI 5–85%)
in preventing laboratory-confirmed influenza (21). In addition,
they found a significant reduction in respiratory illness with fever,
with an associated vaccine efficacy of 29% (95%CI, 7–46). Finally,
maternal influenza vaccination was associated with a 42% (95%
CI 18.2–58.8) reduction in infant clinic visits. Madhi et al. found
that there was a vaccine efficacy rate of 48.8% (95% CI, 11.6–70.4)
in preventing RT-PCR-confirmed influenza. However, there was
not a difference in infants presenting with influenza-like illness or
with any respiratory illness (30).
In addition to the randomized-controlled trials, several other
studies suggest a benefit to the infant from maternal influenza
immunization. Benowitz et al. performed a matched case–control
study with case patients defined as infants under 12months
that were admitted to the hospital due to laboratory-confirmed
influenza between October 2000 and April of 2009 (43). For
each case, one to two infants who tested negative for influenza
were also enrolled. Only 2.2% of the mothers of 91 case subjects
aged <6months had received the influenza vaccination during
pregnancy as compared to 19.9% of 156 controls. The adjusted
vaccine efficacywas 91.5% (95%CI, 61.7–98.1%; p= 0.001). There
was not a significant benefit in infants older than 6months of
age, potentially secondary to the waning of maternal antibodies,
as infants that were vaccinated were excluded from the study.
Poehling et al. performed a similar analysis through use of the
NewVaccine Surveillance Network that monitored admission due
to influenza among infants in three U.S. counties (44). The study
included data from multiple years before the 2009 pandemic and
found that infants of vaccinated mothers <6months of age were
45–48% less likely to be hospitalized for influenza than infants of
unvaccinated mothers.
Another group approached this in a prospective fashion eval-
uating 1169 mother–infant pairs delivering in three consecutive
influenza seasons between December 2002 and March 2005 (45).
In this study, influenza vaccination did not have an impact of the
number of outpatient visits attributable to influenza-like illness.
However, it did significantly reduce hospitalizations secondary
to influenza-like illness and laboratory-confirmed influenza virus
infection by 39 and 41%, respectively. Infants of vaccinated moth-
ers also had significantly higher HI titers to all vaccine strains
comparedwith infants of unvaccinatedmothers. Earlier studies by
Puck and Reuman had demonstrated that infants with increased
cord blood neutralizing antibodies to influenza had delayed infec-
tion with influenza, also suggesting a role for maternal antibodies
in the prevention of influenza disease in infants (46, 47).
Conclusion
Overall, the data indicate that pregnant women mount adequate
and effective responses to influenza vaccination. There is strong
evidence that pregnant women respond at a level that is com-
parable with other healthy adults. Further, there is also good
evidence that protective antibodies are transferred to infants,
with the majority of studies indicating that cord-blood titers are
equivalent to maternal titers at the time of delivery. Although
both second and third trimester vaccinations appear to be equally
efficacious, there is less data on first trimester vaccination. Data
are mixed relative to whether first trimester vaccination results
in diminished cord-blood titers. In some cases, especially fol-
lowing monovalent H1N1 vaccination, cord-blood titers have
been consistently higher than maternal titers. The data mir-
ror those of other vaccines that elicit a primarily IgG1 vac-
cine response, as active placental transfer of antibody through
placental Fc receptors primarily occurs with this class of IgG
(48). The nature of cellular responses to influenza vaccinations
is less well defined; a deficit in interferon production in vitro
has been observed in pregnant women; however, this effect was
rescued by vaccination. Pregnant women have equal and per-
haps increased plasmablast induction compared to non-pregnant
women following IIV.
The robust immunogenicity of influenza vaccination in preg-
nancy correlates with clinical efficacy. The vaccine is effective
at reducing clinical illness in pregnant women at a level on par
with that observed for non-pregnant healthy subjects. In addition,
there is a clear benefit to infants of vaccinatedmothers up through
6months of age, presumably through active transport of maternal
antibody. While not addressed in this review, there is substantial
evidence that influenza vaccination is safe for pregnant women
and the fetus with no evidence that immunization increases the
risk of preterm delivery or other adverse pregnancy outcomes
(19, 49–52). In summary, influenza vaccination is both highly
immunogenic and clinically beneficial for pregnant women and
their infants.
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